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Abstract: Patients with Brugada syndrome (BrS) can show a leftward deviation of the frontal QRS-
axis upon provocation with sodium channel blockers. The cause of this axis change is unclear. In
this study, we aimed to determine (1) the prevalence of this left axis deviation and (2) to evaluate its
cause, using the insights that could be derived from vectorcardiograms. Hence, from a large cohort
of patients who underwent ajmaline provocation testing (n = 1430), we selected patients in whom a
type-1 BrS-ECG was evoked (n = 345). Depolarization and repolarization parameters were analyzed
for reconstructed vectorcardiograms and were compared between patients with and without a >30◦
leftward axis shift. We found (1) that the prevalence of a left axis deviation during provocation testing
was 18% and (2) that this left axis deviation was not explained by terminal conduction slowing
in the right ventricular outflow tract (4th QRS-loop quartile: +17 ± 14 ms versus +13 ± 15 ms,
nonsignificant) but was associated with a more proximal conduction slowing (1st QRS-loop quartile:
+12[8;18] ms versus +8[4;12] ms, p < 0.001 and 3rd QRS-loop quartile: +12 ± 10 ms versus +5 ± 7 ms,
p < 0.001). There was no important heterogeneity of the action potential morphology (no difference
in the ventricular gradient), but a left axis deviation did result in a discordant repolarization (spatial
QRS-T angle: 122[59;147]◦ versus 44[25;91]◦, p < 0.001). Thus, although the development of the
type-1 BrS-ECG is characterized by a terminal conduction delay in the right ventricle, BrS-patients
with a left axis deviation upon sodium channel blocker provocation have an additional proximal
conduction slowing, which is associated with a subsequent discordant repolarization. Whether this
has implications for risk stratification is still undetermined.
Keywords: Brugada syndrome; vectorcardiogram; left axis deviation; ventricular arrhythmias
1. Introduction
In patients suspected of Brugada syndrome (BrS), documenting the spontaneous
type-1 BrS-ECG or, after, provocation testing with a cardiac sodium channel blocker is
a required criterion for the BrS-diagnosis [1]. During such provocation testing, the QRS
axis may deviate towards the left [2,3]. As the right ventricular outflow tract (RVOT) is a
critical area in the development of the type-1 BrS-ECG and its associated malignant arrhyth-
mias [1,4], this left axis deviation may be caused, among others, by exaggerated conduction
slowing in the RVOT exceeding the conduction slowing that is already associated with
the development of the type-1 ECG [1,4,5]. This could result in a diminished rightward
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vector and consequently a more pronounced and leftward vector, resulting in a leftward
axis deviation [1]. Alternatively, this leftward deviation may be due to more proximal
conduction abnormalities. Currently, the prevalence of a left axis deviation in drug-induced
BrS and its origin are unknown. Importantly, when the underlying pathophysiological
mechanisms underlying the ECG variations in BrS are unraveled, this could contribute to
risk stratification.
While the 12-lead ECG is unsuitable for determining the origin of a leftward axis
deviation, vectorcardiography provides more three-dimensional electrophysiological data
and consequently more spatiotemporal information [4,6,7]. For this reason, the vectorcar-
diogram is potentially able to distinguish between conduction slowing in the RVOT and
more proximal conduction abnormalities, thereby providing the opportunity to discover
the origin of the left axis deviation. Furthermore, the vectorcardiogram is also able to pro-
vide additional information on repolarization characteristics [4,8,9], which could provide
additional insights on the electrophysiological effects of axis deviations.
In this study, we evaluated vectorcardiograms of a large cohort of patients suspected
of BrS who underwent provocation testing in order to (1) determine the prevalence of a left
axis deviation in patients with a positive ajmaline test result and (2) to evaluate the cause
of this left axis deviation.
2. Results
2.1. Baseline Characteristics
Figure 1 shows the flowchart of the selection of patients. In total, 345 patients in whom
ajmaline testing elicited a type-1 BrS-ECG (positive test) were identified from a total cohort
of 1430 patients who underwent provocation testing (24.1%). In total, 320 of these 345
(92.8%) patients were included for this study, and 25 (7.2%) patients were excluded due
to incomplete data or an indeterminable axis. The prevalence of a left axis deviation in
patients with a positive test and determinable QRS-axis was 17.5% (n = 56/320). Patients
with a left axis deviation at baseline were more often female and were significantly shorter
and lighter; the BMI, however, did not significantly differ (Table 1). The age, histories of
(possible) arrhythmias, the indication for testing and the administered ajmaline dose, as
well as the percentage of the ajmaline maximal target dose, did not differ (Table 1). The
presence of an SCN5A mutation was also not significantly different between the groups.
Please note that genetic testing was not performed in all patients, in particular when genetic
testing in a family member had already revealed the absence of a potentially causative
mutation. The baseline ECG parameters are presented in Table 1.
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Figure 1. Flowchart of the patient selection. 
Table 1. Baseline characteristics. 
Characteristic Left Axis Deviation (n = 56) No Left Axis Deviation (n = 264) 
Age, years 46 ± 13 45 ± 13 
Male sex 20 (35.7) * 143 (54.2) 
Length, cm 171 ± 10 * 175 ± 11 
Weight, kg 71 ± 16 * 78 ± 14 
BMI, kg/m2 24 ± 4 26 ± 4 
History of SVT, n (%) 0 (0.0) 6 (2.6) 
History of VT/VF, n (%) 1 (2.2) 11 (4.8) 
History of Syncope, n (%) 13 (28.9) 45 (20.4) 
Family history of SCD/ SUD, n (%) 25 (47.2) 134 (52.3) 
Family history of BrS, n (%) 31 (55.4) 135 (51.1) 
Genetic testing, n (%) 35 (62.5) 154 (58.3) 
Likely pathogenic or pathogenic SCN5A variant, 
n (%) 
9 (25.7 ‡) 18 (11.7 ‡) 
Indication for Test 
ECG suspicious for BrS, n (%) 7 (12.5) 56 (21.2) 
Symptoms (Syncope, VT/VF or AF), n (%) 6 (10.7) 18 (6.8) 
Family screening BrS, n (%) 32 (57.1) 134 (50.8) 
Family screening SCD/ SUD, n (%) 11 (19.6) 56 (21.2) 
Ajmaline administered (mg) 72 ± 19 74 ± 24 
Percentage of maximum ajmaline target dose ad-
ministered (%) 
100 ± 22 95 ± 28 
ECG Parameters 
Heart rate (bpm) 66 ± 10 68 ± 1 
PR-interval 168 ± 30 168 ± 29 
QRS-duration (ms) 100 ± 14 * 105 ± 15 
QTc-interval (ms) 425 ± 22 424 ± 28 
Normal QRS-axis, n (%) 53 (94.6) 224 (84.8) 
Left QRS-axis, n (%) 3 (5.4) 23 (8.7) 
Data are presented as the mean±SD or n (%).* = p < 0.05. ‡: of patients who underwent genetic testing, nonsignificant (p = 
0.057). BMI: body mass index, BrS: Brugada syndrome, SCD: sudden cardiac death, SVT: supraventricular tachycardia, 
SUD: sudden unexplained death, VT: ventricular tachycardia, VF: ventricular fibrillation. 
Figure 1. Flowchart of the patient selection.
Int. J. Mol. Sci. 2021, 22, 484 3 of 9
Table 1. Baseline characteristics.
Characteristic Left Axis Deviation (n = 56) No Left Axis Deviation (n = 264)
Age, years 46 ± 13 45 ± 13
Male sex 20 (35.7) * 143 (54.2)
Length, cm 171 ± 10 * 175 ± 11
Weight, kg 71 ± 16 * 78 ± 14
BMI, kg/m2 24 ± 4 26 ± 4
History of SVT, n (%) 0 (0.0) 6 (2.6)
History of VT/VF, n (%) 1 (2.2) 11 (4.8)
History of Syncope, n (%) 13 (28.9) 45 (20.4)
Family history of SCD/ SUD, n (%) 25 (47.2) 134 (52.3)
Family history of BrS, n (%) 31 (55.4) 135 (51.1)
Genetic testing, n (%) 35 (62.5) 154 (58.3)
Likely pathogenic or pathogenic SCN5A variant, n (%) 9 (25.7 ‡) 18 (11.7 ‡)
Indication for Test
ECG suspicious for BrS, n (%) 7 (12.5) 56 (21.2)
Symptoms (Syncope, VT/VF or AF), n (%) 6 (10.7) 18 (6.8)
Family screening BrS, n (%) 32 (57.1) 134 (50.8)
Family screening SCD/ SUD, n (%) 11 (19.6) 56 (21.2)
Ajmaline administered (mg) 72 ± 19 74 ± 24
Percentage of maximum ajmaline target dose
administered (%) 100 ± 22 95 ± 28
ECG Parameters
Heart rate (bpm) 66 ± 10 68 ± 1
PR-interval 168 ± 30 168 ± 29
QRS-duration (ms) 100 ± 14 * 105 ± 15
QTc-interval (ms) 425 ± 22 424 ± 28
Normal QRS-axis, n (%) 53 (94.6) 224 (84.8)
Left QRS-axis, n (%) 3 (5.4) 23 (8.7)
Data are presented as the mean±SD or n (%).* = p < 0.05. ‡: of patients who underwent genetic testing, nonsignificant (p = 0.057). BMI:
body mass index, BrS: Brugada syndrome, SCD: sudden cardiac death, SVT: supraventricular tachycardia, SUD: sudden unexplained death,
VT: ventricular tachycardia, VF: ventricular fibrillation.
2.2. Baseline Vectorcardiogram Parameters
Patients with a positive test and a left axis deviation upon provocation testing had, at
baseline, shorter QRS-durations when compared to patients without a left axis deviation
upon provocation testing (100 ± 14 ms versus 105 ± 15 ms, p < 0.05). In the 3rd quartile
of the QRS-loop, conduction was slightly faster in patients with a left axis deviation
upon provocation (10[8;12] ms versus 12[10;14] ms, p < 0.05). There was no difference in
the depolarization–repolarization interaction in both groups (Table 2, QRS-T angle and
ventricular gradient).
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Table 2. Vectorcardiographic parameters in patients with a left axis deviation of >30◦ at baseline, at ajmaline peak, and the
























QRS duration, ms 100 ± 14 * 105 ± 15 143 ± 21 * 136 ± 20 +43 ± 16 † +31 ± 21
Duration of q1, ms 33 ± 4 33 ± 5 45 ± 8 * 42 ± 8 +12[8;18] † +8[4;12]
Duration of q2, ms 15 ± 3 15 ± 3 18 ± 6 * 20 ± 5 +2[–2;6] † +6[2;8]
Duration of q3, ms 10[8;12] * 12[10;14] 22[14;30] † 14[10;20] +12 ± 10 † +5 ± 7
Duration of q4, ms 42 ± 10 44 ± 11 58 ± 16 57 ± 14 +17 ± 14 +13 ± 15
Frontal axis
QRS-loop, ◦ 29 ± 24 29 ± 36 –74[–107;3]
† 29[0;40] –98[–128;–24] † –6[–27;–1]
Spatial QRS T angle,
◦ 67 ± 27 62 ± 34 122[59;147] † 44[25;91] 39 ± 46 † –1 ± 43
Ventricular gradient,
mV.ms 37 ± 16 41 ± 17 35 ± 13 38 ± 14 –1 ± 7 –3 ± 7
Max. J-amplitude in
V1-V2ic3 (µV) 98.5[59;129] 89[52;142] 311[220;397] 342[245;440] 236 ± 185 246 ± 165
Data are presented as the mean±SD. median [IQR]. Max.: maximum; ms: milliseconds; mV: Millivolts; µV: Microvolts; q1: first quartile of
the QRS-loop; q2: second quartile of the QRS-loop; q3: third quartile of the QRS-loop; q4: fourth quartile of the QRS-loop. * = p < 0.05 and
† = p ≤ 0.001 for patients with a left axis deviation compared to patients with no left axis deviation.
2.3. Vectorcardiogram Parameters at Peak Ajmaline Dose
2.3.1. Depolarization Abnormalities
At the peak ajmaline dose, progressive conduction slowing had occurred in all four
quartiles in both groups (Table 2). Patients with a left axis deviation showed more of a
conduction delay when compared to patients without a left axis deviation (QRS duration:
+43 ± 17 ms versus +30 ± 21 ms, p < 0.001). This conduction delay in patients with a left
axis deviation occurred primarily in the first (+12[8;18] ms versus +8[4;12] ms, p < 0.001)
and third (+12 ± 10 ms versus + 5 ± 7 ms, p < 0.001) quartiles. In the second quartile,
conduction slowing was less pronounced in patients with a left axis deviation (+2[−2;6] ms
versus +6[2;8] ms, p <0.001). Noticeably, the conduction delay in the fourth quartile was
similar in both groups (Table 2). In addition, there were no differences in the amount of
maximal right-precordial ST-elevation (measured at the J-point) between the two groups. In
Figure 2, the QRS-T loops of two representative patients at baseline and ajmaline peak are
shown; from this figure, the conduction slowing at the peak ajmaline dose when compared
to baseline (especially in the patient with left axis deviation) can be appreciated. Figure 3
shows the proportion of patients with a left axis deviation and an increase of the conduction
intervals above the median value of the cohort. For the first (63.3% versus 43.7%, p < 0.05)
and third quartiles (72.7% versus 37.6%, p < 0.001) this proportion was significantly higher
compared to patients without a left axis deviation (Figure 3). For the second quartile, in
contrast, the proportion of patients with conduction slowing was larger in the patients
without a left axis deviation (21.8% versus 35.4%, p = 0.059). The proportion of patients
with conduction slowing above the median of the entire cohort in the fourth quartile was
similar in both groups (52.7% versus 46.4%, p = 0.458) (Figure 3).
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Figure 2. The QRS-T loop in the transverse plane of two representative patients at baseline and ajmaline peak. (a) Patient 
without a left axis deviation. The QRS-axis in the frontal plane changed 3° to the left. At baseline, the QRS-duration was 
94 ms and increased to 106 ms at ajmaline peak; the changes in the duration of the quartiles of the QRS-loops were: q1 +0 
ms, q2 +2 ms, q3 +2 ms and q4 +8 ms. The QRS-T angle changed with –19° from 27° at baseline to 8° at ajmaline peak; (b) 
Patient with a left axis deviation. The QRS-axis in the frontal plane changed 60° to the left. At baseline, the QRS-duration 
was 92 ms and increased to 138 ms at ajmaline peak; the changes in the duration of the quartiles of the QRS-loops were: 
q1 +14 ms, q2 -2 ms, q3 +18 ms and q4 +16 ms. The QRS-T angle changed with +60° from 40° at baseline to 100° at ajmaline 
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without a left axis deviation. The QRS-axis in the frontal p ane changed 3◦ to the l seline, the QRS-duration was 94
ms and increased to 106 ms at ajmaline peak; the changes in the duration of the quartiles of the QRS-loops were: q1 +0
ms, q2 +2 ms, q3 +2 ms and q4 +8 ms. The QRS-T angle changed with –19◦ from 27◦ at baseline to 8◦ at ajmaline peak; (b)
Patient with a left axis deviation. The QRS-axis in the frontal plane changed 60◦ to the left. At baseline, the QRS-duration
was 92 ms and increased to 13 s at ajmaline peak; the ch es in th duration of the quartiles of the QRS-loops w re: q1
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peak. Dashes of the QRS-T loop: 2-ms intervals. The black arrow indicates the QRS-loop direction.
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2.3.2. Repolarization Abnormalities
The spatial QRS-T angle significantly differed at the peak ajmaline dose (Table 2): in
patients with a left axis deviation, the spatial QRS-T angle rose to borderline abnormal
values (>105–135◦) whilst remaining normal in the patients without a left axis deviation
(122[59;147]◦ versus 44[25;91]◦, p < 0.001). The heterogeneity of the action potential mor-
phology, as expressed by the ventricular gradient, did not significantly change or differ
between the two groups at the peak ajmaline dose (Table 2).
3. Discussion
3.1. Main Findings
In this study, we show that (1) the prevalence of a left axis deviation during ajmaline
provocation testing in patients with a positive ajmaline test is 17.5% and (2) that this left
axis deviation is not caused by conduction slowing in the RVOT but is due to additional
conduction slowing in the more proximal conduction system.
The observed left axis deviation could possibly occur due to excessive conduction
slowing in the RVOT, as this is the most commonly affected region in BrS patients [1,4]. Our
results, however, show that the RVOT conduction, as mirrored by the conduction slowing
in the 4th quartile of the QRS-loop, slows in equal amounts between patients with a left
axis deviation and patients without a left axis deviation while they develop the type-1 ECG.
This demonstrates that the RVOT region is equally affected in both groups and that the
cause of the left axis deviation must originate more proximally in the conduction system.
Conduction slowing in BrS patients who developed a left axis deviation was indeed most
prominent in the 1st and 3rd quartiles of the QRS-loop, most likely representing additional
septal and free wall depolarization abnormalities, respectively [7,10–12]. Apparently,
in these patients with a left axis deviation, conduction seems to be more extensively
affected. This could potentially explain some part of the varying arrhythmogenic risk in
BrS-patients [1]. These conductional differences cannot be explained from our results by the
currently known (likely) pathogenic SCN5A mutation, as the mutation status did not differ
significantly between groups. Still, loss-of-function SCN5A mutations will often result in a
more general conduction disease. Surprisingly, at baseline, conduction in the 3rd quartile
is slightly faster in patients with a left axis deviation, whilst out of the four quarters, this
quartile showed the most conduction slowing at the peak ajmaline. If conduction in the
free wall actually is the most extensively affected region, this faster conduction at baseline
is remarkable and against our expectations. The underlying mechanism and the clinical
implications of this finding are unclear and could be the focus of future research. In addition,
global repolarization appeared to be more discordant from depolarization in patients with
a left axis deviation, as indicated by increased, borderline abnormal (>105–135◦), QRST-
angles. In the general population, abnormal (>135◦) and borderline abnormal (105–135◦)
QRS-T angles are strong predictors for cardiac death. One could therefore hypothesize that
patients with a positive test with a concomitant left axis deviation might have a higher
arrhythmogenic risk.
As to the origin of the characteristic ST-elevation (or J-point elevation) that is associated
with the development of a type-1 BrS-ECG, previous studies suggested that excitation
failure at the RVOT was elementary in this process [13,14]. In the current study, the
amount of ST-elevation did not differ between those ajmaline-positive patients with or
without a left axis deviation upon ajmaline provocation. Whether vectorcardiography,
which is dependent on spatial vectors, would be able to add insights to the occurrence
and localization of an excitation failure in the development of the type-1 ECG during
the simultaneous slowing of conduction during type-1 ECG development is currently
uncertain.
3.2. Future Perspective
Future studies may investigate whether the occurrence of a left axis deviation during
ajmaline testing in BrS-patients partly determines their arrhythmogenic risk. Clearly, a
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greater ability to stratify the arrhythmogenic risk in BrS patients would make it possible to
optimize treatments accordingly.
3.3. Limitations
Vectorcardiograms were not recorded using additional orthogonal Frank XYZ leads
but were reconstructed from 12-lead ECGs. Despite the fact that the reconstruction process
using matrix multiplication has been validated, we cannot exclude some degree of vari-
ability from Frank leads [15]. However, we used the same lead setup in every patient and
compared within-patient changes. In addition, by using the reconstructed vectorcardio-
grams, we enabled a future comparison of our data with other cohorts for whom digital
12-lead ECG data is available.
In addition, as this was a retrospective exploratory study, we were not informed
about the follow-up data of these patients so as to determine potential differences in
arrhythmogenic risk or differences in the progression of the clinical phenotype as indicated
by the presence or absence of a (ajmaline-induced) left axis deviation.
4. Materials and Methods
4.1. Patients and Sodium Channel Provocation Testing
In this study, out of a cohort of 1430 patients who underwent provocation testing
during the period from 2009 to 2015, a selection of patients was made based on the
provocation test result and the cardiac axis. All patients for whom the provocation test was
positive (see below) and whose electrocardiogram were available for a vectorcardiogram
reconstruction were selected for this study; those with an abnormal or negative test were
excluded. Tests were defined as (1) positive if a type-1 BrS-ECG occurred [1], (2) abnormal
if arrhythmias or an excessive QRS-widening of ≥40% occurred, and (3) negative if the
target dose was reached and none of the criteria above were met. Ajmaline was used as
the sodium channel blocker and was infused intravenously in boluses of 10 mg/min until
the maximum dose (1 mg/kg) was reached or until a positive or abnormal test result was
obtained. None of the patients had exhibited a spontaneous type-1 BrS ECG before the
provocation test. These patients underwent provocation testing because of symptoms (e.g.,
unexplained syncope or documented ventricular arrhythmias), a baseline ECG that raised
the suspicion of BrS, family screening for BrS or family screening in the context of a sudden
cardiac death or sudden unexplained death.
4.2. Electrocardiographic Recordings, Analysis and Definitions
4.2.1. Electrocardiographic Recordings
Modified 12-lead ECGs—with V3 and V5 placed cranially to V1 and V2 over the third
intercostal space—were recorded at baseline and at one minute after each ajmaline bolus.
4.2.2. Electrocardiographic Analysis
ECGs were analyzed with the electrocardiographic analysis system MEANS, and
its markers settings (e.g., P-wave onset, P-wave offset, QRS onset, etc.) were manually
inspected and adjusted if deemed necessary [16]. Vectorcardiograms were reconstructed
from the 12-lead ECG using the matrix multiplication as previously described [15]. The
vectorcardiographic analysis consisted of dividing the spatial QRS-loop in four quartiles
of equal length. Subsequently, the durations (ms) in the transverse plane were measured
out of these four quartiles. Furthermore, to study the depolarization and repolarization
interaction, the spatial QRS-T angle (◦) and the vector magnitude (mV·ms) (i.e., ventric-
ular gradient) of the spatial QRS-T integral were determined. An abnormally increased
QRS-T angle indicates global discordant repolarization, values of 105–135◦ (borderline
abnormal) and >135 (abnormal) are associated with fatal cardiac arrhythmias in the general
population [8]. The ventricular gradient is considered a three-dimensional measure of the
heterogeneity of the action potential morphology [9]. In order to calculate the change in
the conduction intervals, the vectorcardiographic parameters at baseline were deducted
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from the parameters at the peak ajmaline dose. To further evaluate the four quartiles of
the QRS-loop between patients with a left axis deviation and patients without a left axis
deviation, the proportion of patients with an increase above the median value of the entire
cohort was compared between the two groups.
4.2.3. Electrocardiographic Definitions
A left axis deviation was defined in this study as a leftward shift of the frontal QRS
axis of >30◦ at the peak ajmaline dose as compared to the baseline. We defined the fourth
quartile of the QRS-loop—in patients with a positive ajmaline test—as representative of
RVOT conduction [4].
4.3. Statistical Analysis
The statistical analysis was performed with SPSS Statistics (version 25.0, IBM Corpo-
ration, Armonk, New York, USA). Categorical variables are presented as frequencies and
group percentages. To compare such variables, the Fisher-exact test was used. Continuous
variables are expressed as the mean ± standard deviation in the case of a normal distribu-
tion or the median [interquartile range] in the case of a skewed distribution. Histograms
and Q–Q plots were used to evaluate the distribution of variables with continuous data.
The unpaired two-tailed t-test was used to compare normally distributed variables; in the
case of a skewed distribution, the Mann–Whitney U test was used. A p-value of <0.05 was
accepted as the level of statistical significance.
5. Conclusions
In BrS-patients, a left axis deviation during ajmaline testing occurs in a significant
number of patients. This leftward shift in axis is not caused by an additional conduction
slowing of the RVOT but appears to occur as a consequence of an additional, more proximal
conduction slowing. Whether a left axis deviation can also be used for the stratification of
arrhythmia risk is currently undetermined.
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